VSPharmtech (CEO Park Shin-young) announced on the 17th that it received a commendation from the President of the Korea Health Industry Development Institute at the '2025 Biohealth Global Open Innovation Activation Award' on the 12th.
This award, hosted by the Ministry of Health and Welfare and organized by the Korea Health Industry Development Institute, was established for the first time this year to encourage individuals and organizations that have contributed to the revitalization of the open innovation ecosystem through technological cooperation and joint research in the biohealth field.
VSPharmtech has received numerous awards, including the Minister of Science and ICT and the Minister of SMEs and Startups Award, the Minister of Food and Drug Safety Award from the Ministry of Health and Welfare, and the Korea Health Industry Development Institute Award, further acknowledging its technological prowess and achievements in overseas expansion from various government agencies. The company's currently developing VS-101 anticancer drug enhances anticancer efficacy without increasing toxicity when used in combination with existing anticancer treatments. The drug was developed based on public technology from the Korea Institute of Radiological & Medical Sciences.
VSPharmtech developed VS-101 through an exclusive licensing agreement with the Korea Institute of Radiological and Medical Sciences, and has received approval from the US FDA for phase 2 clinical trials targeting various solid tumors.
The VSPharmtech Research Institute recently announced that complete remission was observed in all patients in a domestic Phase 1 clinical trial for head and neck cancer. Lee Hyun-ho, Director of the Oncology Strategy Research Institute, announced that he has been invited to speak at the 2026 "DDRsummit," an international conference on DNA damage response (DDR). He plans to present the results of his research on novel anticancer mechanisms and discuss joint research with multinational pharmaceutical companies.
CEO Park Shin-young explained, "We are establishing a subsidiary in Boston, USA, and are pursuing Newco investment based on technology transfer for specific indications, such as glioblastoma." She also stated, "We are also in parallel discussions with global pharmaceutical companies interested in the interim results of our Phase 2 clinical trial for head and neck cancer in the US."
- See more related articles
You must be logged in to post a comment.